Inventor · disambiguated record
Michael Hudecek
Also filed as: HUDECEK MICHAEL
7 granted patents·20 pending applications·116 citations·filing 2011–2024
87Inventor score
Files withUNIV WUERZBURG J MAXIMILIANS15HUTCHINSON FRED CANCER RES5RIDDELL STANLEY R2DEPT OF HEALTH AND HUMAN SERVICES THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY1EUROPEAN MOLECULAR BIOLOGY LABORATORY1
Top patents by PatentIndex Score
27 records- 0197US10736918B2Method and compositions for cellular immunotherapyHUTCHINSON FRED CANCER RES·Filed 2017·Granted Aug 11, 2020·24 cites·30 claims
- 0296US10780118B2Method and compositions for cellular immunotherapyHUTCHINSON FRED CANCER RES·Filed 2013·Granted Sep 22, 2020·21 cites·37 claims
- 0396US9163258B2Method for the treatment of obesityRIDDELL STANLEY R·Filed 2011·Granted Oct 20, 2015·41 cites·13 claims
- 0495US10869889B2Method and compositions for cellular immunotherapyHUTCHINSON FRED CANCER RES·Filed 2019·Granted Dec 22, 2020·8 cites·18 claims
- 0589US11065278B2Method and compositions for cellular immunotherapyHUTCHINSON FRED CANCER RES·Filed 2018·Granted Jul 20, 2021·3 cites·11 claims
- 0689US9987308B2Method and compositions for cellular immunotherapyRIDDELL STANLEY R·Filed 2012·Granted Jun 5, 2018·16 cites·31 claims
- 0785US2024390491A1Method and compositions for cellular immunotherapyFRED HUTCHINSON CANCER CENTER·Filed 2024·Application pending·0 cites
- 0880US11149073B2ROR1-specific chimeric antigen receptors (CAR) with humanized targeting domainsUNIV WUERZBURG J MAXIMILIANS·Filed 2018·Granted Oct 19, 2021·3 cites·14 claims
- 0971US2021052649A1Method and compositions for cellular immunotherapyHUTCHINSON FRED CANCER RES·Filed 2020·Application pending·0 cites
- 1070US2023277591A1Use of flt3 car-t cells and flt3 inhibitors to treat acute myeloid leukemiaUNIV WUERZBURG J MAXIMILIANS·Filed 2022·Application pending·0 cites
- 1169US2023310432A1Control and modulation of the function of gene-modified chimeric antigen receptor t cells with dasatinib and other tyrosine kinase inhibitorsUNIV WUERZBURG J MAXIMILIANS·Filed 2022·Application pending·0 cites
- 1267US2025361284A1Transposase fusion proteins for use in cell and gene therapyUNIV WUERZBURG J MAXIMILIANS·Filed 2023·Application pending·0 cites
- 1360US2021169880A1Control and modulation of the function of gene-modified chimeric antigen receptor t cells with dasatinib and other tyrosine kinase inhibitorsUNIV WUERZBURG J MAXIMILIANS·Filed 2018·Application pending·0 cites
- 1458US2020206266A1Use of flt3 car-t cells and flt3 inhibitors to treat acute myeloid leukemiaUNIV WUERZBURG J MAXIMILIANS·Filed 2018·Application pending·0 cites
- 1557US2022064258A1Ror1-specific chimeric antigen receptors (car) with humanized targeting domainsUNIV WUERZBURG J MAXIMILIANS·Filed 2021·Application pending·0 cites
- 1656US2023303975A1Modified lymphocytesUNIV WUERZBURG J MAXIMILIANS·Filed 2021·Application pending·0 cites
- 1755US2023242641A1Slamf7 carsUNIV WUERZBURG J MAXIMILIANS·Filed 2021·Application pending·0 cites
- 1855US2023287129A1Siglec-6-binding polypeptidesUNIV WUERZBURG J MAXIMILIANS·Filed 2021·Application pending·0 cites
- 1954US2023346734A1Combination therapy of atra or other retinoids with immunotherapeutic agents binding to bcmaUNIV WUERZBURG J MAXIMILIANS·Filed 2021·Application pending·0 cites
- 2051US2022306719A1Ultramodular igg3-based spacer domain and multi-function site for implementation in chimeric antigen receptor designUNIV WUERZBURG J MAXIMILIANS·Filed 2020·Application pending·0 cites
- 2151US2016095883A1Method for the treatment of obesityDEPT OF HEALTH AND HUMAN SERVICES THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY·Filed 2015·Application pending·0 cites
- 2249US2023143003A1Affinity matured and humanized binding domains targeting ror2UNIV WUERZBURG J MAXIMILIANS·Filed 2021·Application pending·0 cites
- 2346US2022145332A1Cell penetrating transposaseEUROPEAN MOLECULAR BIOLOGY LABORATORY·Filed 2020·Application pending·0 cites
- 2444US2020209240A1Cd19cart cells eliminate myeloma cells that express very low levels of cd19UNIV WUERZBURG J MAXIMILIANS·Filed 2018·Application pending·0 cites
- 2543US2022364056A1Short-chain fatty acid pentanoate as enhancer for cellular therapy and anti-tumor therapyPHILIPPS UNIV MARBURG·Filed 2020·Application pending·0 cites
- 2640US2019350980A1Compositions and methods for transplant recipient conditioningPAPAYANNOPOULOU THALIA·Filed 2018·Application pending·0 cites
- 2736US2019169637A1A method for high level and stable gene transfer in lymphocytesUNIV WUERZBURG J MAXIMILIANS·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Michael Hudecek files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →